- Home
- ATEC vs TARS Comparison
ATEC vs TARS Comparison
Compare ATEC & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATEC | TARS |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.8B |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ATEC | TARS |
|---|---|---|
| Price | $20.67 | $79.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | $21.70 | ★ $76.56 |
| AVG Volume (30 Days) | ★ 2.1M | 376.9K |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $728,020,000.00 | $366,100,000.00 |
| Revenue This Year | $26.83 | $147.24 |
| Revenue Next Year | $16.61 | $53.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 27.11 | ★ 182.44 |
| 52 Week Low | $8.70 | $38.51 |
| 52 Week High | $22.66 | $85.25 |
Technical Indicators
Market Signals| Indicator | ATEC | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 56.70 | 59.02 |
| Support Level | $20.87 | $77.44 |
| Resistance Level | $21.65 | $82.90 |
| Average True Range (ATR) | 0.70 | 3.43 |
| MACD | -0.22 | -0.18 |
| Stochastic Oscillator | 47.06 | 53.07 |
Price Performance
Historical ComparisonAbout ATEC Alphatec Holdings Inc.
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.